pharmacokinetics in the critically ill
DESCRIPTION
Jeff Lipman explores how our conventional regimes for drug administration may be drastically underperforming when treating our critically ill patientsTRANSCRIPT
![Page 1: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/1.jpg)
Pharmacokinetics in the critically ill
Department of
Intensive Care MedicineRoyal Brisbane Hospital University of Queensland
Professor Jeffrey Lipman
![Page 2: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/2.jpg)
![Page 3: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/3.jpg)
Pharmacokinetics in the critically ill
Department of
Intensive Care MedicineRoyal Brisbane Hospital University of Queensland
Professor Jeffrey LipmanUnless you understand this
DRUGS DON’T WORK
![Page 4: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/4.jpg)
Intensive Care Med 2013; 39: 2070-2082
December 2013
![Page 5: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/5.jpg)
Important conceptRecommended dosages are obtained from
healthy volunteers and possibly (ward) “sick” patients
![Page 6: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/6.jpg)
Clinical pharmacology:drug development
Antibiotic regimens are derived from non-critically ill volunteers. Their haemodynamic system is normal, as is their liver and kidney blood flow. They have not leaky capillaries nor have they drips and pipes in every orifice.
![Page 7: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/7.jpg)
![Page 8: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/8.jpg)
SEPSIS
Increased Cardiac Output
Leaky Capillaries &/or altered protein binding
End Organ Dysfunction (e.g. renal or hepatic)
Increased CL Increased Vd Decreased CL
Low Plasma Concentrations
High Plasma Concentrations
Normal Organ Function
Normal Plasma Concentrations
Unchanged Vd
Roberts and Lipman Critical Care Medicine 2009; 37:840-851
![Page 9: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/9.jpg)
LOW EXPOSURE TO ANTIBIOTICS ENABLES
DEVELOPMENT OF RESISTANCE
Critical Care Medicine August 2008;36:2433-40
![Page 10: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/10.jpg)
Cmax Peak ConcentrationCmin Trough Concentrationt1/2 Half-life
V (or VD) Volume of distribution
AUC Area under curveCl Clearance
Protein binding
Antibiotic related IMPORTANTIMPORTANTpharmacokinetic parameters
![Page 11: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/11.jpg)
Volume of Distribution
![Page 12: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/12.jpg)
Gous et al Anaesth Intens Care 1995
![Page 13: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/13.jpg)
Gous et al Anaesth Intens Care 1995
![Page 14: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/14.jpg)
AMIKACIN DATA Marik P. Anaesth Intens Care 1993
![Page 15: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/15.jpg)
….we have found that higher-than-recommended loading and daily doses of vancomycin seem to be necessary to rapidly achieve therapeutic serum concentrations.
35mg/kg loading 35mg/kg/day
![Page 16: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/16.jpg)
Col
istin
CM
SSTANDARD DOSE INSUFFICIENT
Plachouras et al Antimicrob Agents Chemother 2009;53:3420-6
![Page 17: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/17.jpg)
Antibiotics that stay in extravascular and extracellular space ie that don’t penetrate “solid” organs, (hydrophilic tendencies) namely AMINOGLYCOSIDES
GLYCOPEPTIDES
β-LACTAMS (to a lesser extent)
COLISTIN
VOLUME OF DISTRIBUTIONALTERATIONS IN ICU
![Page 18: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/18.jpg)
DOSE ADJUSTMENT – MESSAGE 1
LOADING DOSE
INCREASED VOLUME OF DISTRIBUTION MEANS LOADING DOSE
TO “FILL UP ALL SPACES”
![Page 19: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/19.jpg)
Critical Care Medicine March 2009Revised from Clinical Pharmacokinetics 2006
![Page 20: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/20.jpg)
Increased CL
Critical Care Medicine March 2009Revised from Clinical Pharmacokinetics 2006
![Page 21: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/21.jpg)
Increased CL
Critical Care Medicine March 2009Revised from Clinical Pharmacokinetics 2006
![Page 22: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/22.jpg)
1
100
0 4 8 12
Time (hr)
Co
nc
en
tra
tio
n (
mg
/L) (A)
1
100
0 4 8 12
Time (hr)
Co
nc
en
tra
tio
n (
mg
/L)
(B)
1st dose Day 3-6
1. Cefpirome levels lower2. No difference between D1 vs later dose
CEFEPIME (O) vs CEFPIROME ()�
![Page 23: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/23.jpg)
0
50
100
150
200
250
0 50 100 150 200 250 300Creatinine Clearance (mL/min)
Dru
g C
lea
ran
ce (m
L/m
in)
Cefepime CefpiromeLipman et al Anesth Analg 2003
Creatinine clearance
![Page 24: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/24.jpg)
0
50
100
150
200
250
0 50 100 150 200 250 300Creatinine Clearance (mL/min)
Dru
g C
lea
ran
ce (m
L/m
in)
Cefepime Cefpirome
Creatinine clearance
Augmented Renal ClearanceCr Cl>130ml/min
Lipman et al Anesth Analg 2003
![Page 25: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/25.jpg)
![Page 26: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/26.jpg)
AUGMENTED RENAL CLEARANCE – who gets it?
![Page 27: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/27.jpg)
Those manifesting ARC were younger (P <0.001), male (P = 0.012), with lower acute physiology and chronic health evaluation (APACHE) II (P= 0.008) and modified sequential organ failure assessment (SOFA) scores (P = 0.013), and higher cardiac indices (P = 0.013). In multivariate analysis, age ≤50 years, trauma, and a modified SOFA score ≤4, were identified as significant risk factors.
AUGMENTED RENAL CLEARANCE – who gets it?
![Page 28: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/28.jpg)
UDY et al Critical Care Medicine March 2014: 42 : 520-527
![Page 29: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/29.jpg)
Measurements and Main Results: …. Overall, 65.1% manifested augmented renal clearance on at least one occasion during the first seven study days; themajority (74%) of whom did so on more than or equal to 50% of their creatinine clearance measures.
65.1%
UDY et al Critical Care Medicine March 2014: 42 : 520-527
![Page 30: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/30.jpg)
AUGMENTED RENAL CLEARANCE – how long does it last?
UDY et al Critical Care Medicine March 2014: 42 : 520-527
![Page 31: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/31.jpg)
Conclusions: Augmented renal clearance appears to be a common finding in this patient group, with sustained elevation of creatinine clearance throughout the first week in ICU.
UDY et al Critical Care Medicine March 2014: 42 : 520-527
![Page 32: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/32.jpg)
IN SUMMARY
Younger patients who have an inflammatory response (any) with “normal” renal function
Particularly those that need fluid loading and or inotropic support to defend a blood pressure
AUGMENTED RENAL CLEARANCE – who gets it?
![Page 33: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/33.jpg)
AUGMENTED RENAL CLEARANCE
CHEST 2012; 142(1):30–39
![Page 34: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/34.jpg)
Trough conc/MIC ratio vs Creat Cl
Udy et al Chest 2012;142:30-39
![Page 35: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/35.jpg)
ARC pictorial explanation
Udy et al Clin Pharmacokinet 2010; 49:1-16
![Page 36: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/36.jpg)
IF YOU DON’T LOOK PROPERLYYOU WON’T SEE IT.
![Page 37: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/37.jpg)
DOSE ADJUSTMENT – MESSAGE 2
INCREASE FREQUENCY
INCREASED CLEARANCES MEANS LOW TROUGHS
FOR AB’s THAT NEED t>MIC NEED TO INCREASE FREQUENCY
![Page 38: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/38.jpg)
Critically ill patients have lowered protein concentrations and thus altered protein binding, unpredictable volumes of distribution, and vastly altered clearances compared to non-critically ill patients.
Protein binding
![Page 39: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/39.jpg)
More than 40% of all patients had a baseline serum albumin concentration of 25 g/l or less
AT BASELINE
2006;333:1044
![Page 40: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/40.jpg)
1
10
100
1000
0 200 400 600 800 1000 1200 1400 1600
Time (min)
Pla
sma
ceftr
iaxo
ne c
once
ntra
tion
(mg/
L)
Joynt et al J Antimicrob Chemother 2001
TOTAL UNBOUND/FREE
CEFTRIAXONE
![Page 41: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/41.jpg)
ERTAPENEM 1GM/DAY (?..!)
Level ‘therapeutic’ target = 100% f T>MIC
DOSE INCR 1GM BD
DOSE INCR 1GM TDS
DOSE INCR 1GM TDSAS EXTENDED INFUSION
DOSE INCR 1GM TDSAS EXTENDED INFUSION
and only then did we get adequate levels!
![Page 42: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/42.jpg)
More than 40% of all patients had a baseline serum albumin concentration of 25 g/l or less
AT BASELINE
2006;333:1044
![Page 43: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/43.jpg)
DOSE ADJUSTMENT – MESSAGE 3
INCREASE FREQUENCY
BEWARE HIGHLY PROTEIN BOUNDANTIBIOTICS
USUALLY MEANS QUICKER ELLIMINATION (in ICU)
![Page 44: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/44.jpg)
Reviewed in Clinical Pharmacokinetics January 2011
Reviewed in Clinical Pharmacokinetics January 2013
![Page 45: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/45.jpg)
Sepsis changes PK
Extracorporeal circuits
Altered CL and Increased Vd cf AKI
? Plasma concentrations
![Page 46: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/46.jpg)
Kidney Filter
Ultrafiltrate Dialysate
FLOW
FLOW
Semi-permeable Membrane
(C)RRT(Continuous) Renal
Replacement Therapy
![Page 47: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/47.jpg)
Ultrafiltrate
FLOW
Semi-permeable Membrane
CRRT Effects on Electrolytes and Water ..…
and Drugs.
+/- Dialysate
UrCr
K Ca PO4
UrCrCr
CrCr
UrUr
K Ca PO4
H2OH2O
FLOW
![Page 48: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/48.jpg)
BEST WE HAVE
Choi et al Crit Care Med 2009;37:2268-82
![Page 49: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/49.jpg)
DOSE ADJUSTMENT – MESSAGE 4
COME DO A PhD WITH US
EXTRACORPOREAL CIRCUITS
??
![Page 50: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/50.jpg)
Sepsis changes PK
Extracorporeal circuits
Altered CL and Increased Vd cf AKI
? Plasma concentrations
If dosing does not account for these changes – sub-optimal therapy!
Sub-optimal patient outcomes
![Page 51: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/51.jpg)
TDM DEFINITION
Therapeutic Drug Monitoring (TDM)
refers to analysis and subsequent interpretation of drug concentrations in biological fluids
![Page 52: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/52.jpg)
PLACE
TDM should be used to
maximise efficacy
minimize toxicity
To personalise dosing for high probability of therapeutic success, prevent development of resistance, provide low probability of toxicity
![Page 53: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/53.jpg)
AMINOGLYCOSIDES AND GLYCOPEPTIDES
Assays developed for side-effect profiles
Large market to prevent toxicity
Rapid turnaround, easy to use immunoassays
TDM should be used to
maximise efficacy
minimize toxicity
![Page 54: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/54.jpg)
BETA-LACTAMS
Safe drugs
Large therapeutic range
TDM should be used to
maximise efficacyminimize toxicity
![Page 55: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/55.jpg)
J Chromatogr B 2010;878:2039-2043
![Page 56: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/56.jpg)
Roberts JA et al. Int J Antimicrob Agents 2010;36:332-39
Roberts JA, Hope WW, Lipman J. Int J Antimicrob Agents 2010;35:419-20
![Page 57: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/57.jpg)
Roberts JA et al. Int J Antimicrob Agents 2010;36:332-39
A total of 236 patients were subject to TDM over an 11-month period. The mean ± standard deviation age was 53.5 ± 18.3 years. Dose adjustment was required in 175 (74.2%) of the patients, with 119 of these patients (50.4%) requiring dose increases after the first TDM.
Dose adjustment was required in 175 (74.2%)
![Page 58: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/58.jpg)
For various reasons therapeutic drug monitoring (TDM) of most antibiotics is difficult but not impossible. We have set up a TDM service for all our beta-lactam use and have (not surprisingly ) shown that in more than half of our ICU patients we are dose adjusting once receiving back a drug level!
MESSAGE 5
![Page 59: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/59.jpg)
MAIN DIFFERENCES IN ICU
Increased volume of distribution
Increased cardiac output
Increased hepatic and renal blood flows
Low serum proteins, hence protein binding
Increased clearances
Renal replacement techniques unique to ICUs
![Page 60: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/60.jpg)
Sepsis changes PK
Extracorporeal circuits
Altered CL and Increased Vd cf AKI
? Plasma concentrations
If dosing does not account for these changes – sub-optimal therapy!
Sub-optimal patient outcomes
![Page 61: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/61.jpg)
DOSE ADJUSTMENT – MESSAGE 1
LOADING DOSE
INCREASED VOLUME OF DISTRIBUTION MEANS LOADING DOSE
TO “FILL UP ALL SPACES”
![Page 62: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/62.jpg)
DOSE ADJUSTMENT – MESSAGE 2
INCREASE FREQUENCY
INCREASED CLEARANCES MEANS LOW TROUGHS
FOR AB’s THAT NEED t>MIC NEED TO INCREASE FREQUENCY
![Page 63: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/63.jpg)
DOSE ADJUSTMENT – MESSAGE 3
INCREASE FREQUENCY
BEWARE HIGHLY PROTEIN BOUNDANTIBIOTICS
USUALLY MEANS QUICKER ELLIMINATION (in ICU)
![Page 64: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/64.jpg)
DOSE ADJUSTMENT – MESSAGE 4
EXTRACORPOREAL CIRCUITS
??
![Page 65: Pharmacokinetics in the Critically Ill](https://reader034.vdocuments.mx/reader034/viewer/2022042714/54bf90324a7959dc418b456f/html5/thumbnails/65.jpg)
For various reasons therapeutic drug monitoring (TDM) of most antibiotics is difficult but not impossible. We have set up a TDM service for all our beta-lactam use and have (not surprisingly ) shown that in more than half of our ICU patients we are dose adjusting once receiving back a drug level!
MESSAGE 5